leisure time -WSS

leisure time

author：focus 2025-08-23 08:54:30 - browse：18

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

WSS

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Why Novartis is going to walk from its acquisition of MorphoSys

Surgery pushed Ben Carson to fame

Readout LOUD: Venture capital, Gilead, and more M&A

Report cites 'urgent' need to recruit more diverse clinical trial participants

Global cancer cases to surge 77% by 2050, WHO report says

entertainment

leisure time

entertainment

Hollywood unions extend contract negotiations for actors

Study gives hint on South Asians’ higher risk of cardiovascular disease

Bright Health sells Medicare Advantage business to Molina

Congress must protect the remaining independent doctors

Anesthesiologist group: stop taking Ozempic before surgery

The Biogen Aduhelm mess could happen again

Drug repurposing or repositioning? The language matters

Doctors on social media are being harassed and cyberbullied

Peter Hotez and the public health issue of online harassment

AstraZeneca stays mum on Medicare drug pricing negotiations

hotspot

AstraZeneca stays mum on Medicare drug pricing negotiations

Latigo launches with $135 million for Vertex

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Websites selling Wegovy, Zepbound ingredients targeted by FDA

leisure time

entertainment

focus

hotspot